EGFR and neoplasm: CD73, a key enzyme governing adenosine production, has been reported to regulate cancer progression by suppressing the anti‐tumor immunity within the TME.[30] In TCGA dataset, the expression of NT5E, the CD73‐encoding gene, was detected to be significantly higher in EGFR‐mutant NSCLC tumors than that in the WT group (p = 0.0330) (Figure 4a).